XNAS
HOWL
Market cap59mUSD
Jun 12, Last price
1.29USD
1D
4.88%
1Q
7.50%
IPO
-92.07%
Name
Werewolf Therapeutics Inc
Chart & Performance
P/E
—
P/S
30.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.88%
Rev. gr., 5y
%
Revenues
2m
-90.55%
Net income
-71m
L+88.70%
CFO
-56m
L+72.29%
Profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 1,885 -90.55% | 19,943 21.60% | 16,401 | |||
Cost of revenue | 75,479 | 99,352 | 74,967 | |||
Unusual Expense (Income) | ||||||
NOPBT | (73,594) | (79,409) | (58,566) | |||
NOPBT Margin | ||||||
Operating Taxes | (2,246) | |||||
Tax Rate | ||||||
NOPAT | (73,594) | (79,409) | (56,320) | |||
Net income | (70,515) 88.70% | (37,368) -27.53% | (51,564) 3.61% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 23,576 | 18,329 | 16,191 | |||
BB yield | -36.32% | -13.32% | -27.36% | |||
| Debt | ||||||
Debt current | 1,557 | 8,275 | 2,084 | |||
Long-term debt | 20,427 | 56,248 | 27,284 | |||
Deferred revenue | 433 | 1,128 | ||||
Other long-term liabilities | 28,924 | 191 | ||||
Net debt | (90,231) | (69,820) | (101,161) | |||
| Cash flow | ||||||
Cash from operating activities | (56,188) | (32,612) | (40,596) | |||
CAPEX | (254) | (769) | (3,611) | |||
Cash from investing activities | (254) | (769) | (3,611) | |||
Cash from financing activities | 13,080 | 58,429 | 15,906 | |||
FCF | (71,071) | (76,804) | (57,446) | |||
| Balance | ||||||
Cash | 112,215 | 134,343 | 129,315 | |||
Long term investments | 1,214 | |||||
Excess cash | 112,121 | 133,346 | 129,709 | |||
Stockholders' equity | (414,583) | (344,069) | (306,702) | |||
Invested Capital | 527,889 | 507,799 | 445,042 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 43,860 | 35,647 | 28,864 | |||
Price | 1.48 -61.66% | 3.86 88.29% | 2.05 -82.79% | |||
Market cap | 64,912 -52.82% | 137,596 132.54% | 59,171 -81.81% | |||
EV | (25,319) | 67,776 | (41,990) | |||
EBITDA | (71,780) | (77,645) | (57,462) | |||
EV/EBITDA | 0.35 | 0.73 | ||||
Interest | 4,656 | 3,139 | 1,104 | |||
Interest/NOPBT | ||||||